Goldman Sachs starts Gubra at “neutral,” cites balanced risk and limited upside

Goldman Sachs has initiated coverage on Danish biotechnology firm Gubra A/S with a "neutral" rating and a Dkr520 12-month price target, representing a 23.9% upside. While acknowledging strong prospects for its amylin asset GUBAmy, which has an estimated $5 billion peak sales potential and an AbbVie partnership, alongside a profitable CRO business supporting its obesity pipeline, Goldman cited limited valuation upside relative to broader European biotech peers and a balanced risk-reward profile given competitive pressures from established players.

Analysis

Goldman Sachs has initiated coverage on Gubra A/S with a 'neutral' rating and a 12-month price target of Dkr520, which represents a notable 23.9% upside from its current price. The analysis highlights Gubra's unique hybrid model, where a profitable and steadily growing Contract Research Organisation (CRO) business, characterized by above-sector margins, provides a stable financial foundation to fund its high-potential R&D pipeline focused on obesity. The central asset, GUBAmy, an amylin analogue, is identified as the primary value driver, with Goldman estimating a potential $5 billion peak sales opportunity. This asset is strategically positioned as a therapy for patients intolerant to GLP-1 treatments and is significantly de-risked by a commercialization partnership with AbbVie. However, the 'neutral' rating is justified by a 'balanced risk-reward profile,' as the stock's current valuation is seen as offering limited upside compared to broader European biotech peers. Furthermore, Gubra faces substantial competition from established players in the obesity market, including Novo Nordisk, Zealand Pharma, and Eli Lilly, which tempers the otherwise strong fundamental outlook.

Key Decisions for Investors

• Investors should weigh the significant 23.9% price target upside against the 'neutral' rating, which indicates that the current valuation may already reflect much of the near-term potential.
• Consider the company's differentiated business model, where the profitable CRO segment offers a degree of downside protection not typically seen in development-stage biotech firms.
• Closely monitor clinical data and commercialization milestones for the key asset GUBAmy, as its success against formidable competitors like Novo Nordisk and Eli Lilly is critical to unlocking long-term value.